Phase II trial of 10-EDAM in the treatment of metastatic breast cancer

This phase II trial was conducted to assess the efficacy and safety of 10-Ethyl-10-Deaza-Aminopterin (10-EDAM), a folate antagonist, in metastatic breast cancer patients who had received no more than one prior chemotherapy regimen. Fifty-five patients were treated on an initial weekly dose 80 mg/m(2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2007-06, Vol.60 (1), p.61-67
Hauptverfasser:	BEINART, Garth A, GONZALEZ-ANGULO, Ana M, YOUNG, James A, HORTOBAGYI, G. N, BROGLIO, Kristine, FRYE, Debbie, WALTERS, Ronald, HOLMES, Frankie Ann, GUNALE, Shivaji, BOOSER, Daniel, ROSENTHAL, Julian, DHINGRA, Kapil
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Agranulocytosis - chemically induced Alopecia - chemically induced Aminopterin Aminopterin - adverse effects Aminopterin - analogs & derivatives Aminopterin - therapeutic use Anemia - chemically induced Anticancer properties Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Antitumor activity Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - secondary Chemotherapy Disease Progression Female Folic acid Gynecology. Andrology. Obstetrics Humans Leukopenia - chemically induced Mammary gland diseases Medical sciences Metastases Metastasis Middle Aged Nausea - chemically induced Neutropenia Patients Pharmacology. Drug treatments Stomatitis Survival Analysis Time Factors Toxicity Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!